Ivonescimab Plus Chemo Extends Squamous NSCLC Survival - PubMed
4 hours ago
- #Clinical Trial
- #Immunotherapy
- #Lung Cancer
- Ivonescimab, an anti-PD-1 and anti-VEGF bispecific antibody, combined with chemotherapy significantly improves overall survival in advanced squamous non-small cell lung cancer (NSCLC).
- The trial, conducted in China, compared this combination to an immunotherapy-chemotherapy combination.
- Questions persist regarding the trial's applicability to patients outside of China.